1. What Is the Pancreatic Cancer mRNA Vaccine Market?
The Pancreatic Cancer mRNA Vaccine Market covers individualised neoantigen mRNA vaccines targeting patient-specific PDAC mutations to stimulate tumour-specific T cell response. Products encompass personalised mRNA neoantigen vaccine, lipid nanoparticle delivery, mRNA-dendritic cell vaccine, and combination with checkpoint inhibitor. Market dynamics reflect Phase 2 mRNA neoantigen vaccine data generating clinical validation, poor PDAC prognosis creating high unmet need, and mRNA platform enabling personalised vaccine within 6 weeks.
2. Pancreatic Cancer mRNA Vaccine Market Size & Forecast
3. Emerging Technologies
- Whole exome sequencing identifying top 20 neoantigen target per patient within 2 weeks are advancing. Growing development is driven by personalised vaccine antigen selection speed improvement.
- Lipid nanoparticle formulation achieving tumour-infiltrating lymphocyte expansion from mRNA antigen are advancing. Growing investment is driven by delivery efficiency improvement for solid tumour immune activation.
- Combination mRNA neoantigen with anti-CTLA-4 achieving dual checkpoint blockade enhancement are advancing. Growing investment is driven by pancreatic tumour immune exclusion overcome requirement.
- Off-the-shelf shared neoantigen vaccine targeting KRAS G12D mutation in most PDAC are advancing. Growing investment is driven by manufacturing cost reduction versus personalised approach.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Early Toxicity Testing Market.
4. Key Market Opportunity
Demand is strongest in the Pancreatic Cancer mRNA Vaccine Market at the Phase 3 personalised adjuvant programme, where Moderna and Merck drive the largest investment. Combination with checkpoint inhibitor creates a clinical development opportunity as PD-1 combination benefit sustains combination trial. KRAS shared neoantigen creates an off-the-shelf opportunity as G12D targeting enables non-personalised approach. Asia Pacific creates expansion as Chinese and South Korean mRNA oncology pipeline grows.
5. Top Companies in the Pancreatic Cancer mRNA Vaccine Market
The following organisations hold leading positions in the Pancreatic Cancer mRNA Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Moderna (mRNA-4157)
- Merck (Pembrolizumab Combo)
- BioNTech (Autogene Cevumeran)
- Genentech (Roche)
- Neon Therapeutics
- Oncobiologics
- Geneos Therapeutics
- Turnstone Biologics
- Agenus (Neoantigen)
- Nuvation Bio
6. Market Segmentation
The Pancreatic Cancer mRNA Vaccine Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | Personalised Neoantigen mRNA mRNA-DC Vaccine Combination with PD-1 Inhibitor Adjuvant mRNA Vaccine |
| By Stage | Phase 1 Phase 2 Pre-Clinical Post-Surgical Adjuvant |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Pancreatic Cancer mRNA Vaccine Market trajectory over the forecast period:
Moderna and Merck Achieve Phase 2 Pancreatic mRNA Vaccine Clinical Milestone.Moderna mRNA-4157 with Merck pembrolizumab achieving Phase 2 pancreatic vaccine efficacy signal in 2024 demonstrates personalised mRNA cancer vaccine at clinical validation milestone. Moderna achieving 44 percent relapse-free survival improvement over pembrolizumab alone demonstrates the mRNA neoantigen clinical benefit.
BioNTech and Genentech Achieve Personalised Cancer Vaccine Phase 1 Milestone.BioNTech autogene cevumeran and Genentech achieving Phase 1 safety and neoantigen T cell response in 2024 demonstrate the second programme validating the mRNA neoantigen approach. BioNTech achieving clonal neoantigen T cell expansion demonstrates the immune mechanism supporting the clinical benefit hypothesis.
Clinical Programme Achieves Pancreatic Vaccine Manufacturing Under 6 Weeks Turnaround.Clinical programme achieving patient-specific mRNA vaccine manufacturing under 6 weeks from surgical sample to first dose in 2024 demonstrates personalised manufacturing feasibility. Six-week turnaround demonstrating compatibility with adjuvant treatment window demonstrates the manufacturing milestone.
For related market intelligence, see the Regenerative Medicine Market.
8. Segmental Analysis
By type, the Personalised Neoantigen mRNA Vaccine segment dominated in 2025 as the largest clinical investment with Moderna and BioNTech driving programme value. The Combination with PD-1 Inhibitor segment is the fastest-growing development segment, advancing as pembrolizumab combination achieves Phase 2 efficacy signal.
By stage, Phase 2 Clinical dominated in 2025 by investment.
9. Regional Analysis
Regional demand patterns across the Pancreatic Cancer mRNA Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Pancreatic Cancer mRNA Vaccine Market in 2025, holding 50.7% of the global market. Biopharmaceutical companies, cancer immunology research institutions, and clinical oncology programmes are advancing pancreatic cancer mRNA vaccine development through clinical trial execution, antigen identification, and personalised neoantigen vaccine manufacture. FDA breakthrough therapy designation interest and strong NIH investment in personalised cancer vaccine research are encouraging biopharmaceutical investment in mRNA oncology vaccine development. Strong oncology research infrastructure, established mRNA technology platform capability, and high venture capital investment in cancer immunotherapy are generating regional development activity.
Highest CAGR Region
Europe is expected to register the highest CAGR of 38.43% during the forecast period. European biopharmaceutical companies, academic cancer research institutions, and clinical oncology organisations across Germany, the Netherlands, France, and the United Kingdom are advancing pancreatic cancer mRNA vaccine development through clinical trials and translational research programmes. EMA breakthrough therapy pathway and growing European pharmaceutical investment in personalised mRNA cancer vaccine platforms are encouraging development. Rising clinical evidence from early mRNA cancer vaccine trials and growing European oncology research investment are generating development activity.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Pancreatic Cancer mRNA Vaccine Market was valued at USD 480.30 Mn in 2025 and is projected to reach USD 6,004.90 Mn by 2034, growing at a CAGR of 32.4% over the 2026–2034 forecast period.
The Pancreatic Cancer mRNA Vaccine Market is projected to grow at a CAGR of 32.4% from 2026 to 2034.
North America accounted for the largest share of the Pancreatic Cancer mRNA Vaccine Market in 2025, holding 50.7% of the global market.
The leading companies in the Pancreatic Cancer mRNA Vaccine Market include Moderna (mRNA-4157), Merck (Pembrolizumab Combo), BioNTech (Autogene Cevumeran), Genentech (Roche), Neon Therapeutics, Oncobiologics, Geneos Therapeutics, Turnstone Biologics, Agenus (Neoantigen), Nuvation Bio.
Moderna and merck achieve phase 2 pancreatic mrna vaccine clinical milestone.
By type, the Personalised Neoantigen mRNA Vaccine segment dominated in 2025 as the largest clinical investment with Moderna and BioNTech driving programme value.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.